On this page
What are Caroli Disease and Caroli Syndrome?
Bile is a digestive fluid produced in the liver and transported to the intestine through a network of channels called bile ducts, where it helps digest dietary fats. When these ducts become abnormally widened, bile stagnates and accumulates instead of flowing freely. This creates an ideal environment for recurrent bacterial infections, a condition known as cholangitis.
Caroli disease, also known as congenital intrahepatic biliary dilatation, is a rare genetic condition.
- Dilatation: Abnormal widening of the bile ducts
- Biliary: Relating to the bile duct system (the channels connecting the liver, gallbladder, and intestine)
- Congenital: Present from birth (due to a developmental anomaly)
- Intrahepatic: Affecting the bile ducts within the liver itself
In its classic form, Caroli disease is characterized by recurring episodes of bile duct inflammation (cholangitis) and the absence of hepatic fibrosis (the scarring process that replaces normal functional liver tissue). It is typically diagnosed during adolescence or early adulthood.
Caroli Disease vs. Caroli Syndrome: A Critical Distinction
| Caroli Disease | Caroli Syndrome | |
|---|---|---|
| Defining features | Bile duct malformations only | Bile duct malformations + congenital hepatic fibrosis |
| Occurrence | Sporadic (most cases without family history); rare autosomal dominant exceptions | Genetic; often associated with autosomal recessive polycystic kidney disease (ARPKD) |
| Prevalence | ~1 in 1,000,000 | ~1 in 100,000 |
| Inheritance | Typically sporadic | Autosomal recessive |
Caroli syndrome, the more common of the two forms, is more serious because it also involves hepatic fibrosis. It is also more frequently associated with kidney involvement.
These prevalence figures are estimates, as the rarity of both conditions makes precise epidemiological data difficult to obtain.
Treatment is primarily supportive, centered on antibiotics for infections and, when necessary, endoscopic procedures such as endoscopic retrograde cholangiopancreatography (ERCP) to relieve biliary obstruction.
Causes
Caroli syndrome is caused by a mutation in the PKHD1 gene, which is responsible for encoding a protein called fibrocystin, also known as polyductin. In the liver, fibrocystin plays a critical role in regulating bile composition: it detects mechanical, chemical, and osmotic signals and modifies bile properties accordingly. It is also involved in normal liver and kidney development through the regulation of cell proliferation.
When the PKHD1 gene is defective, fibrocystin is absent or non-functional, resulting in:
- Abnormal widening (dilatation) of the intrahepatic bile ducts: bile stagnates and becomes progressively thicker, forming biliary sludge. This can lead to calculus (stone) formation and obstruction.
- Hepatic fibrosis is an uncontrolled wound-healing response that deposits excessive scar tissue in place of healthy liver tissue. Over time, it progressively replaces normal liver architecture.
- A fertile environment for recurrent bacterial infections (cholangitis).
The same PKHD1 gene is responsible for autosomal recessive polycystic kidney disease (ARPKD), explaining why the two conditions frequently co-occur in the same patient. Because Caroli disease shares similar characteristics, a PKHD1 alteration may also be involved; however, this has not yet been definitively established.
Caroli disease was first described in the late 1950s by Dr. Jacques Caroli, a French gastroenterologist, who identified the condition as a distinct clinical entity.
Genetic Transmission of Caroli Syndrome
Caroli syndrome follows an autosomal recessive inheritance pattern. This is particularly true when it is associated with ARPKD. Note that the more common form of polycystic kidney disease has autosomal dominant transmission.
- For a disease to be expressed, the defective gene must be inherited from both parents.
- A person who receives one functional and one defective copy of the gene will be a carrier. This individual is generally asymptomatic because the functioning gene compensates.
Inheritance probabilities when both parents are carriers:
| Outcome | Probability per pregnancy |
|---|---|
| Child affected (inherits two defective copies) | 25% |
| Child is a carrier (like the parents) | 50% |
| Child inherits two functional copies (unaffected, non-carrier) | 25% |
Symptoms
Symptoms of both Caroli disease and Caroli syndrome typically present around the age of 30, though they can manifest at any age, from infancy to old age.
Because the condition can affect both the liver and kidneys, clinical manifestations reflect involvement of both organs. Since the kidneys are often the first organ affected, the condition frequently first appears in newborns as polycystic kidneys. These are kidneys that contain multiple fluid-filled cysts within the normal kidney tissue.
Hepatic manifestations typically appear later in life, reflecting the different expression timeline of the affected protein in liver tissue.
The progressive stagnation of bile in the abnormally dilated intrahepatic ducts leads to:
- Formation of biliary sludge (thickened bile)
- Progression to true biliary stasis (flow blockage)
- Development of gallstones and biliary obstruction
- Recurrent bacterial cholangitis (bile duct infections)
Characteristic Symptoms of Cholangitis Episodes
- Abdominal pain, usually in the right upper quadrant.
- Fever and chills, which reflect the infectious process.
- Enlarged liver (hepatomegaly).
- Jaundice, the yellowing of the skin and whites of the eyes, occurs due to cholestasis: bile accumulation in the blood.
- Pruritus (itching), which is caused by elevated circulating bilirubin levels that irritate skin nerve endings.
The classic triad of fever, right upper quadrant pain, and jaundice (known as Charcot’s triad) is highly suggestive of acute bacterial cholangitis.
Complications
In a minority of patients, particularly those in whom the disease presents at an older age after hepatic fibrosis has developed, severe complications of portal hypertension may emerge:
- Ascites: a pathological accumulation of fluid in the abdominal cavity.
- Oesophageal varices are dilated, fragile blood vessels in the oesophagus. They carry a high risk of life-threatening hemorrhage.
Why Portal Hypertension Develops
The liver contains a complex internal vascular network, known as the portal venous system. This system carries blood directly from the digestive organs to the liver for filtration. In hepatic fibrosis, progressive scarring distorts and obstructs this vascular architecture, causing a gradual buildup of blood pressure within the portal vessels (portal hypertension).
Cancer Risk
Patients with Caroli disease and Caroli syndrome face a significantly increased risk of developing cholangiocarcinoma, which is a malignant tumor of the bile ducts. This risk is related to the chronic inflammation and biliary stasis that repeatedly stimulate and damage the ductal epithelium over time. Long-term oncological surveillance is therefore an essential component of follow-up.
Diagnosis
Caroli disease is typically diagnosed following the first clinical episode of cholangitis, which draws medical attention to the underlying biliary abnormalities.
Laboratory Investigations
Blood tests characteristically reveal:
- Leukocytosis (elevated white blood cell count), which reflects the immune response to infection.
- Elevated alkaline phosphatase (ALP), a marker of biliary obstruction and liver cell damage.
- Elevated liver transaminases (ALT, AST) in active disease.
Imaging Studies
Abdominal ultrasound is the first-line imaging investigation because it offers excellent cost-effectiveness, wide availability, and a non-invasive approach. It can identify intrahepatic biliary dilatation, sludge, and gallstones.
When additional detail is needed:
- CT scan (Computed Tomography): Provides detailed cross-sectional anatomy of the biliary tree, liver parenchyma, and associated structures; useful for planning interventions.
- Endoscopic Retrograde Cholangiopancreatography (ERCP): Direct visualization and treatment of the bile ducts. This method allows simultaneous therapeutic interventions, such as stone extraction and stent placement, during the same procedure. This is a significant advantage.
- Magnetic Resonance Cholangiopancreatography (MRCP): Non-invasive, radiation-free detailed imaging of the biliary tree; the preferred modality for diagnostic mapping when intervention is not immediately required.
Liver Biopsy
Rarely performed in routine cases of Caroli disease, hepatic biopsy is a minimally invasive procedure that collects a small tissue sample. It is used specifically to confirm the presence of hepatic fibrosis when Caroli syndrome is suspected. This helps distinguish it from the purely ductal form of Caroli disease.
Treatment
The prognosis of Caroli disease and syndrome varies considerably depending on:
- The severity of the genetic abnormality and its expression
- The number and extent of organs involved (liver alone vs. liver + kidneys)
- The frequency and severity of cholangitis episodes
- The presence and degree of hepatic fibrosis
Management of Acute Cholangitis
Antibiotic therapy targeting the responsible bacteria (most commonly gram-negative enteric organisms) is the cornerstone of treatment for acute episodes. For patients with obstructive cholangitis:
- Minimally invasive biliary drainage: Performed endoscopically (ERCP) or percutaneously under imaging guidance, to decompress the obstructed bile ducts
- Stone extraction via ERCP when calculi are causing or contributing to the obstruction
Long-Term Pharmacological Management
- Ursodeoxycholic acid (UDCA): A bile acid that reduces bile viscosity and improves bile flow; may reduce biliary sludge formation and the frequency of cholangitis episodes in selected patients
Surgical Options
For patients with severe or anatomically favorable disease:
- Partial hepatectomy (liver resection): This procedure involves removing the affected liver segment or segments. It is particularly considered when the biliary abnormalities are predominantly unilateral (confined to one lobe), since this approach allows targeted removal of the diseased segment while preserving functional liver tissue.
Management of Caroli Syndrome Complications
When hepatic fibrosis is present, as in Caroli syndrome, its progressive complications require dedicated management. This approach follows strategies similar to those used in liver cirrhosis.
- Beta-blockers (e.g., propranolol, carvedilol): Reduce portal pressure and lower the risk of variceal bleeding
- Diuretics (e.g., spironolactone, furosemide): Manage ascites and fluid retention
- Endoscopic variceal ligation (banding): Treats oesophageal varices to prevent or control haemorrhage
- Oncological surveillance: Regular imaging (ultrasound or MRI) and tumour marker monitoring to detect cholangiocarcinoma at the earliest possible stage
Liver Transplantation
Liver transplantation is currently the only definitive curative treatment available for Caroli syndrome and is indicated when:
- Severe hepatic decompensation (liver failure) develops, as shown by refractory ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, or coagulopathy.
- Recurrent or refractory cholangitis fails to respond to medical and endoscopic management.
- Malignant transformation (cholangiocarcinoma) is detected under specific criteria permitting transplant eligibility.
Combined liver-kidney transplantation may be considered for patients with concomitant end-stage renal disease from ARPKD.
Sources and Bibliography
- Umar J, Kudaravalli P, John S. Caroli Disease. StatPearls. NCBI Bookshelf. Updated 2023.
- National Organization for Rare Disorders (NORD) – Caroli Disease.
- Yonem O, Bayraktar Y. Clinical characteristics of Caroli’s disease. World Journal of Gastroenterology. 2007;13(13):1930–1933.
- Raynaud P, Tate J, Callens C, et al. A classification of ductal plate malformations based on anatomic involvement of the biliary system. Gastroenterology. 2011;141(3):1018–1028.
- Desmet VJ. Congenital diseases of intrahepatic bile ducts: variations on the theme of the ductal plate malformation. Hepatology. 1992;16(4):1069–1083.
- Shneider BL, Brown MB, Haber B, et al. A multicenter study of the outcome of biliary atresia in the United States from 1997 to 2000. Journal of Pediatrics. 2006, referenced for context on congenital biliary conditions.
